|本期目录/Table of Contents|

[1]杨可为,郝元斌,邹巧根.LC-MS/MS方法测定比格犬血浆中沙芬酰胺及其代谢物[J].生物加工过程,2017,15(04):70-76.[doi:10.3969/j.issn.1672-3678.2017.04.012]
 YANG Kewei,HAO Yuanbin,ZOU Qiaogen.Determination of safinamide and its metabolites in beagle dog plasma by LC-MS/MS[J].Chinese Journal of Bioprocess Engineering,2017,15(04):70-76.[doi:10.3969/j.issn.1672-3678.2017.04.012]
点击复制

LC-MS/MS方法测定比格犬血浆中沙芬酰胺及其代谢物()
分享到:

《生物加工过程》[ISSN:1672-3678/CN:32-1706/Q]

卷:
15
期数:
2017年04期
页码:
70-76
栏目:
出版日期:
2017-07-30

文章信息/Info

Title:
Determination of safinamide and its metabolites in beagle dog plasma by LC-MS/MS
文章编号:
1672-3678(2017)04-0070-07
作者:
杨可为郝元斌邹巧根
南京工业大学 药学院,江苏 南京 211800
Author(s):
YANG KeweiHAO YuanbinZOU Qiaogen
College of Pharmacy,Nanjing Tech University,Nanjing 211800,China
关键词:
沙芬酰胺 代谢物 药代动力学 LC-MS/MS
分类号:
R969.1
DOI:
10.3969/j.issn.1672-3678.2017.04.012
文献标志码:
A
摘要:
建立液相色谱-质谱联用/质谱(LC-MS/MS)测定比格犬血浆中沙芬酰胺异构体及其代谢物浓度的方法,在此基础上对沙芬酰胺异构体及其代谢物在比格犬体内的药代动力学进行研究。色谱检测条件方法一为用AS-RH手性柱测定沙芬酰胺异构体; 方法二为用XB-C18分析柱测定沙芬酰胺代谢物。质谱条件离子源为APCI源,离子化方式为正离子模式,喷雾电压5 200 V,加热毛细管温度550 ℃,雾化气(N2)流速75.8 KPa,气帘气(N2)75.8 KPa,碰撞气(N2)55.16 KPa,扫描方式为多反应监测(MRM)。建立的LC-MS/MS方法线性范围左旋沙芬酰胺为10~2 000 ng/mL(r=0.999 4),右旋沙芬酰胺为10~2 000 ng/mL(r=0.997 6),沙芬酰胺代谢物为10~1 000 ng/mL(r=0.994 1)。本方法灵敏,快速且稳定,适用于沙芬酰胺异构体及其代谢物药代动力学研究。

参考文献/References:

[1] DéZSI L,VéSCAI L.Safinamide for the treatment of Parkinson’s disease[J].Expert Opin Investing Drug,2014,23(5):729-742.
[2] JOST W H,ENGEMANN K.Drug treatment of Parkinson’s disease:self-assessment of patients in a cross-sectional survey[J].Aktuelle Neurologie,2016,43:428-434.
[3] LEURATTI C,SARDINA M,VENTURA P,et al.Disposition and metabolism of safinamide,a novel drug for Parkinson’s disease,in healthy male volunteers[J].Pharmacology,2013,92:207-216.
[4] GRIZZI F.Cancer heterogeneity and drug metabolism:what we know and what we need to know[J].Future Oncol,2016,12(11):1317-1319.
[5] DAL B L,MAZZUCCHELLI P,Fibbioli M,et al.Bioassay of safinamide in biological fluids of humans and various animal species[J].Arzneimittel-Forschung,2006,56(12):814-819.
[6] MARZO A,DAL BO L,MONTI N C,et al.Pharmacokinetics and pharmacodynamics of safinamide,a neuroprotectant with antiparkinsonian and anticonvulsant activity[J].Pharmacol Res,2004,50(1):77-85.
[7] KUMAR R S,MEYYANATHAN S N,GOWRAMMA B.A validated chiral liquid chromatographic method for the enantiomeric separation of orphenadrine citrate in pharmaceutical dosage form[J].Curr Pharma Anal,2016,12:357-364.
[8] MAZZUCCHELLI P,FIBBIOLI M,MARZO A,et al.Bioassay of safinamide in biological fluids of humans and various animal species[J].Arzneimittel-forschung-drug research,2006,56(12):814-819.
[9] ZHANG K,XUE N,SHI X W,et al.A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate,a new anti-Parkinson drug[J].J Pharma Biomed Anal,2010,55(1):220-224.
[10] CAO N,LIU L,HAO Y B.Simultaneous determination of rabeprazole enantiomers and their four metabolites afterintravenous administration in beagle dogs by a stereoselective HPLC-MS/MS method and itsapplication in pharmacokinetic studies[J].Anal Methods,2016,8(6):1405-1414.

备注/Memo

备注/Memo:
收稿日期:2016-12-04
作者简介:杨可为(1992—),男,江苏南京人,研究方向:药剂学; 邹巧根(联系人),教授,E-mail:zouqiaogen@healthnice.net.
更新日期/Last Update: 2017-07-30